Neurona Therapeutics

Executive Summary

Neurona Therapeutics is a clinical-stage biotherapeutics company pioneering regenerative allogeneic cell therapies for chronic neurological disorders. Its lead candidate, NRTX-1001, is a first-in-class inhibitory neuron therapy designed to treat drug-resistant epilepsy by permanently integrating into neural circuits to restore balanced electrical activity. With a Phase 3 trial planned for 2026, the therapy offers potential long-lasting, possibly curative effects from a single dose, addressing a significant unmet need in epilepsy where about one-third of patients do not respond to existing treatments. Neurona's platform utilizes fully differentiated, allogeneic inhibitory neurons that can be delivered via stereotactic injection, aiming to rebalance excitatory and inhibitory signals in the brain. The upcoming Phase 3 trial represents a critical inflection point, as positive results could support regulatory registration. With its novel mechanism and regenerative approach, Neurona stands at the forefront of cell therapy for neurological diseases, and success in epilepsy could expand the platform to other conditions characterized by neural hyperexcitability.

Upcoming Catalysts (preview)

• Q2 2026FDA clearance to initiate Phase 3 trial for NRTX-100190% success
• H2 2026Dosing of first patient in Phase 3 trial85% success
• Q4 2026Interim safety and efficacy data from ongoing Phase 1/2 trial75% success